[go: up one dir, main page]

AR079152A1 - Inhibidores de glucosilceramida sintasa - Google Patents

Inhibidores de glucosilceramida sintasa

Info

Publication number
AR079152A1
AR079152A1 ARP100104348A ARP100104348A AR079152A1 AR 079152 A1 AR079152 A1 AR 079152A1 AR P100104348 A ARP100104348 A AR P100104348A AR P100104348 A ARP100104348 A AR P100104348A AR 079152 A1 AR079152 A1 AR 079152A1
Authority
AR
Argentina
Prior art keywords
salt
hemitartrate
compound represented
structural formula
formula
Prior art date
Application number
ARP100104348A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR079152(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR079152A1 publication Critical patent/AR079152A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Hemitartrato de formula (1), que puede utilizarse en aplicaciones farmacéuticas. Las formas cristalinas unicas particulares de Hemitartrato de formula (1) se caracterizan por una variedad de propiedades y mediciones físicas. También, se desvelan métodos para producir Hemitartrato cristalino de formula (1), y utilizarlo para inhibir glucosilceramida sintasa o reducir las concentraciones de glicoesfingolípidos en sujetos para tratar un numero de enfermedades. También se describen las composiciones farmacéuticas. Reivindicacion 1: La sal de hemitartrato de un compuesto representado por la formula estructural (1) en donde la sal es una sal amorfa. Reivindicacion 2: La sal de hemitartrato de un compuesto representado por la formula estructural (1) en donde al menos el 70% en peso de la sal es cristalina. Reivindicacion 3: La sal de hemitartrato de un compuesto representado por la formula estructural (1) en donde al menos 70% en peso de la sal está en una forma cristalina unica. Reivindicacion 4: La sal de hemitartrato de un compuesto representado por la formula estructural (1) en donde al menos el 99% en peso de la sal es cristalina. Reivindicacion 5: La sal de hemitartrato de un compuesto representado por la formula estructural (1) en donde al menos 99% en peso de la sal está en una forma cristalina unica.
ARP100104348A 2009-11-27 2010-11-24 Inhibidores de glucosilceramida sintasa AR079152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27

Publications (1)

Publication Number Publication Date
AR079152A1 true AR079152A1 (es) 2011-12-28

Family

ID=43431870

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP100104348A AR079152A1 (es) 2009-11-27 2010-11-24 Inhibidores de glucosilceramida sintasa
ARP210100683A AR121612A2 (es) 2009-11-27 2021-03-18 Inhibidores de glucosilceramida sintasa
ARP210100682A AR121611A2 (es) 2009-11-27 2021-03-18 Inhibidores de glucosilceramida sintasa

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP210100683A AR121612A2 (es) 2009-11-27 2021-03-18 Inhibidores de glucosilceramida sintasa
ARP210100682A AR121611A2 (es) 2009-11-27 2021-03-18 Inhibidores de glucosilceramida sintasa

Country Status (40)

Country Link
US (6) US11458119B2 (es)
EP (5) EP2504332B2 (es)
JP (6) JP2013512252A (es)
KR (6) KR20200013105A (es)
CN (5) CN112521366A (es)
AR (3) AR079152A1 (es)
AU (3) AU2010324810B2 (es)
BR (1) BR112012012947B8 (es)
CA (3) CA3140959A1 (es)
CL (2) CL2012001348A1 (es)
CR (1) CR20120277A (es)
CY (3) CY1115880T1 (es)
DK (3) DK2796457T3 (es)
DO (2) DOP2012000141A (es)
EA (3) EA029990B1 (es)
EC (2) ECSP12011926A (es)
ES (4) ES2586947T3 (es)
GT (1) GT201200161A (es)
HR (3) HRP20140780T4 (es)
HU (2) HUE045784T2 (es)
IL (4) IL310635A (es)
LT (2) LT2796457T (es)
MA (1) MA33838B1 (es)
ME (1) ME02477B (es)
MX (2) MX381242B (es)
MY (2) MY192644A (es)
NI (1) NI201200096A (es)
NZ (3) NZ600155A (es)
PE (2) PE20121337A1 (es)
PH (2) PH12015502514B1 (es)
PL (4) PL3599237T3 (es)
PT (4) PT2796457T (es)
RS (3) RS53503B2 (es)
SG (2) SG10201407881WA (es)
SI (3) SI2796457T1 (es)
SM (1) SMT201600273B (es)
TN (1) TN2012000237A1 (es)
TW (3) TWI586663B (es)
UA (1) UA113491C2 (es)
WO (1) WO2011066352A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
CN103764824B (zh) * 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
SI2753346T1 (sl) 2011-09-07 2020-09-30 Mount Sinai School Of Medicine Ceramidaza in diferenciacija celic
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
LT2854910T (lt) 2012-06-01 2020-05-25 Icahn School Of Medicine At Mount Sinai Ceramido lygiai infekcijos gydymo ir prevencijos metu
HUE046113T2 (hu) 2013-03-14 2020-02-28 Icahn School Med Mount Sinai Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai
US10227323B2 (en) * 2013-09-20 2019-03-12 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
EP3164128A4 (en) * 2014-07-03 2018-02-28 Dr. Reddy's Laboratories Ltd. Amorphous form of eliglustat hemitartarate
ES2716420T3 (es) 2015-04-14 2019-06-12 Sandoz Ag Clorhidrato de eliglustat cristalino
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MX2018006250A (es) 2015-11-18 2018-09-05 Genzyme Corp Biomarcador de enfermedad poliquistica renal y usos del mismo.
MX381953B (es) 2016-02-25 2025-03-13 Asceneuron S A Sales de derivados de piperazina obtenidas por adicion de acidos.
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
JP7045726B2 (ja) 2017-06-16 2022-04-01 ベータ ファーマ，インコーポレイテッド Ｎ－（２－（２－（ジメチルアミノ）エトキシ）－４－メトキシ－５－（（４－（１－メチル－１ｈ－インドール－３－イル）ピリミジン－２－イル）アミノ）フェニル）アクリルアミドおよびその塩の医薬品製剤
US12472144B2 (en) * 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
WO2019030645A1 (en) 2017-08-08 2019-02-14 Kashiv Pharma Llc Pharmaceutical composition comprising eliglustat
AU2018386182B2 (en) 2017-12-15 2024-03-28 Genzyme Corporation Methods for treating Gaucher disease
US12064414B2 (en) 2017-12-20 2024-08-20 Aizant Drug Research Solutions Private Limited. Stable amorphous Eliglustat premix and process for the preparation thereof
US11760741B2 (en) 2018-05-02 2023-09-19 Kashiv Biosciences, Llc Pro-drugs of eliglustat
US20210113703A1 (en) * 2018-05-27 2021-04-22 Bioasis Technologies Inc. Treatment of gaucher disease
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
IL309862A (en) * 2021-07-05 2024-02-01 Ferrer Int Medicines that include glycosidase inhibitors
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
NZ269847A (en) 1993-08-13 1996-11-26 Seikagaku Kogyo Co Ltd 2-alkylamino-3-morpholino-1-propanol derivative in a composition for neuronal disease treatment
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
AU691886B2 (en) 1994-02-02 1998-05-28 Transave, Inc. Pharmaceutically active compounds and liposomes, and methods of use thereof
CA2192555C (en) 1994-06-10 2005-01-11 Jinichi Inokuchi 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
EP1098642B1 (en) 1998-07-27 2007-04-04 Johns Hopkins University Diamino-propanol-compounds for treating ischemia
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
JP2003521479A (ja) * 1999-07-09 2003-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
CZ20023775A3 (cs) 2000-04-24 2003-10-15 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrát
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
EP1358172B1 (en) 2001-01-10 2009-11-18 The Regents of The University of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
BR0116803A (pt) * 2001-01-18 2004-02-17 Merck Patent Gmbh Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
CA2453978C (en) 2001-07-16 2011-10-11 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
ATE539062T1 (de) 2001-08-08 2012-01-15 Tobira Therapeutics Inc Bizyklishe verbindung, ihre herstellung und verwendung
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
EP2011489A3 (en) 2002-07-09 2009-04-22 Roberta Gottlieb Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
WO2005070938A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
CA2580537C (en) 2004-09-17 2015-04-21 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
CA2582022C (en) 2004-09-30 2021-05-18 Vanda Pharmaceuticals, Inc. Methods for the administration of iloperidone
MX2007004514A (es) 2004-10-13 2007-05-09 Pharmacia & Upjohn Co Llc Formas cristalinas de 3-[5-cloro-4-[(2,4-difluorobencil)oxi]-6 oxopirimidin-1(6h)-il]-n-(2-hidroxetil)-4-metilbenzamida.
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
US20070088082A1 (en) * 2005-09-28 2007-04-19 Judith Aronhime Polymorphic forms of ladostigil tartrate
CA2624340A1 (en) * 2005-10-03 2007-04-12 Mallinckrodt Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
WO2007134086A2 (en) * 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
MX2009007254A (es) * 2007-01-12 2009-08-12 Wyeth Corp Composiciones de tableta en tableta.
JP2010523578A (ja) * 2007-03-30 2010-07-15 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いるファブリー病の治療方法
MX2009011473A (es) * 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
EP2594565B1 (en) * 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090307181A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
DK3415515T3 (da) 2009-11-27 2020-03-16 Adverio Pharma Gmbh Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat
CN103619840B (zh) 2011-06-21 2016-01-20 诺华股份有限公司 (s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
CN105753846B (zh) 2019-11-15
DK2796457T3 (en) 2016-08-29
ECSP18063798A (es) 2020-02-28
EP2796457A1 (en) 2014-10-29
IL283935A (en) 2021-07-29
RS53503B1 (sr) 2015-02-27
ME02477B (me) 2017-02-20
KR20200013105A (ko) 2020-02-05
NI201200096A (es) 2012-10-30
SG10201407881WA (en) 2015-01-29
IL310635A (en) 2024-04-01
PT2504332E (pt) 2014-09-02
MA33838B1 (fr) 2012-12-03
SI2796457T1 (sl) 2016-10-28
HK1203485A1 (en) 2015-10-30
EP3599237A1 (en) 2020-01-29
WO2011066352A1 (en) 2011-06-03
TWI586663B (zh) 2017-06-11
KR20120115972A (ko) 2012-10-19
CL2012001348A1 (es) 2012-08-24
SI3133070T1 (sl) 2019-11-29
KR20180049255A (ko) 2018-05-10
PL2796457T3 (pl) 2017-04-28
NZ715108A (en) 2017-06-30
CY1117996T1 (el) 2017-05-17
PH12012501048A1 (en) 2013-02-04
MY192644A (en) 2022-08-29
EP2504332B1 (en) 2014-06-04
JP2013512252A (ja) 2013-04-11
ES2754398T3 (es) 2020-04-17
JP6370264B2 (ja) 2018-08-08
CR20120277A (es) 2012-09-05
PL2504332T3 (pl) 2014-10-31
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
PL2504332T5 (pl) 2021-08-23
EA201592195A1 (ru) 2016-04-29
US20130137743A1 (en) 2013-05-30
CA3140959A1 (en) 2011-06-03
AR121612A2 (es) 2022-06-22
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
JP7150528B2 (ja) 2022-10-11
HUE045784T2 (hu) 2020-01-28
CN102712629A (zh) 2012-10-03
EP3896069A1 (en) 2021-10-20
IL260299A (en) 2018-08-30
MY160542A (en) 2017-03-15
AU2017265180A1 (en) 2017-12-14
AU2016202591B2 (en) 2017-11-30
TW201737910A (zh) 2017-11-01
CA2781676A1 (en) 2011-06-03
AU2016202591A1 (en) 2016-05-19
PL3133070T3 (pl) 2020-01-31
RS53503B2 (sr) 2021-07-30
HK1172031A1 (en) 2013-04-12
ES2493940T3 (es) 2014-09-12
US11458119B2 (en) 2022-10-04
CN102712629B (zh) 2016-10-12
RS54978B1 (sr) 2016-11-30
SG10201800136QA (en) 2018-02-27
EP3133070A1 (en) 2017-02-22
AU2010324810A1 (en) 2012-06-07
JP2016138124A (ja) 2016-08-04
EP3133070B1 (en) 2019-08-14
LT3133070T (lt) 2019-11-11
TW201639562A (zh) 2016-11-16
HRP20191647T1 (hr) 2019-12-13
PL3599237T3 (pl) 2021-09-27
BR112012012947B1 (pt) 2021-04-06
CA2781676C (en) 2020-05-05
IL219892A0 (en) 2012-07-31
RS59543B1 (sr) 2019-12-31
CY1115880T1 (el) 2017-01-25
JP2020189873A (ja) 2020-11-26
JP2019001809A (ja) 2019-01-10
GT201200161A (es) 2014-01-27
TW201130822A (en) 2011-09-16
JP2015212291A (ja) 2015-11-26
PH12015502514B1 (en) 2022-07-29
CN105777707B (zh) 2020-10-13
US12465586B2 (en) 2025-11-11
US20160166542A1 (en) 2016-06-16
KR20250005503A (ko) 2025-01-09
EA023923B1 (ru) 2016-07-29
DK3133070T3 (da) 2019-11-11
MX381242B (es) 2025-03-12
EP2504332B2 (en) 2021-03-17
EA029990B1 (ru) 2018-06-29
HRP20140780T4 (hr) 2021-08-06
ES2875382T3 (es) 2021-11-10
WO2011066352A8 (en) 2011-08-11
EA201890254A3 (ru) 2019-02-28
CA3075788A1 (en) 2011-06-03
BR112012012947A2 (pt) 2017-03-01
EP3599237B1 (en) 2021-03-24
PT2796457T (pt) 2016-07-14
EP2796457B1 (en) 2016-05-18
CA3075788C (en) 2021-12-21
CY1122698T1 (el) 2021-03-12
LT2796457T (lt) 2016-09-12
DK2504332T4 (da) 2021-06-07
KR20220162824A (ko) 2022-12-08
BR112012012947B8 (pt) 2021-05-25
TN2012000237A1 (en) 2013-12-12
JP2023116764A (ja) 2023-08-22
HRP20140780T1 (en) 2014-11-07
UA113491C2 (xx) 2017-02-10
SI2504332T1 (sl) 2014-09-30
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
DOP2016000250A (es) 2017-02-15
US10888547B2 (en) 2021-01-12
KR20150125734A (ko) 2015-11-09
US20230172903A1 (en) 2023-06-08
DOP2012000141A (es) 2012-09-30
DK2504332T3 (da) 2014-08-25
ECSP12011926A (es) 2012-07-31
PT3133070T (pt) 2019-11-11
JP6452635B2 (ja) 2019-01-16
ES2493940T5 (es) 2021-11-23
CL2016002589A1 (es) 2017-05-19
PT3599237T (pt) 2021-04-28
CN112521366A (zh) 2021-03-19
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
NZ600155A (en) 2014-10-31
ES2586947T3 (es) 2016-10-19
TWI656873B (zh) 2019-04-21
AU2017265180B2 (en) 2019-08-01
EA201890254A2 (ru) 2018-10-31
EA201270646A1 (ru) 2013-01-30
SI2504332T2 (sl) 2021-08-31
HUE029371T2 (en) 2017-02-28
SMT201600273B (it) 2016-08-31
PE20171255A1 (es) 2017-08-28
HRP20161038T1 (hr) 2016-10-21
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
CN112521367B (zh) 2024-01-02
CN112521367A (zh) 2021-03-19
MX2012006083A (es) 2012-06-19
EP2504332A1 (en) 2012-10-03
US20160120842A1 (en) 2016-05-05
US20210369672A1 (en) 2021-12-02
PH12015502514A1 (en) 2016-08-15

Similar Documents

Publication Publication Date Title
AR079152A1 (es) Inhibidores de glucosilceramida sintasa
ECSP14004812A (es) Triazolopiridinas sustituidas
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
UY32490A (es) Inhibidores de beta-secretasa
UY32062A (es) Inhibidores de beta-secretasa
ECSP13013011A (es) Triazolopiridinas
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
ECSP099328A (es) Análogos de pirazol
UY33584A (es) Nuevos compuestos benzamida de inhibidores lrrk2
TH129186A (th) สารประกอบเฮทเทอโรไซคลิก (heterocyclic compounds) ซึ่งมีประโยชน์เป็นสารยับยั้ง pdk1 (pdk1 inhibitors)
CU20100014A7 (es) Derivados de pirimidina útiles para el tratamiento de enfermedades inflamatorias o alérgicas
BRPI0907504A2 (pt) forma cristalinia de um compopsto , composição farmacêutica, uso de um composto, e, método para produzir um efeito inibidor de 11bhsd1

Legal Events

Date Code Title Description
FC Refusal